Hodgkin Lymphoma FREE Webinar!

About this event

Lymphoma Australia are hosting a webinar with renowned expert and Haematologist Dr Nicole Wong Doo. In this webinar, Dr Wong Doo will provide information on key updates in Hodgkin Lymphoma, and with Lymphoma Australia answer your questions about the launch of the Australian App MyHodgkin MyHeath.

About Dr Wong Doo

Nicole Wong Doo is a haematologist at Concord Repatriation General Hospital, senior lecturer at the University of Sydney and NSW Councillor for the Haematology Society of Australia and New Zealand.

As Director of the Haematology Clinical Research Unit at Concord Hospital since 2022, she leads a team of 20 in the delivery of clinical trials embedded within clinical practice and clinical-translational research. She is a principal investigator of a number of lymphoma and myeloma clinical trials.

With a growing profile in research focused on listening to patients’ voice through patient-reported outcomes (PRO) research, she leads a PRO study investigating patients’ unmet needs during therapy for blood diseases and is co-PI of MyHodgkin MyHealth, a mobile App for patient-entered health outcomes in Hodgkin lymphoma.

There is limited availability for this event, so secure your spot quickly.

This event has already taken place.

Details

Date: Thursday 6th of March 2025

Time: 5:00pm AEDT - 6:00pm AEDT

Venue: Online virtual event.

For more information contact the Nurse Support Line on 1800 953 081.

Support and information

Patient Online Forum

Find Out More

Order Our Resources

Find Out More

Fundraise for us

Get started

Contact Lymphoma Australia Today!

Patient Support Hotline

General Enquiries

Please note: Lymphoma Australia staff are only able to reply to emails sent in English language.

For people living in Australia, we can offer a phone translation service. Have your nurse or English speaking relative call us to arrange this.

Useful Definitions

Refractory: This means the lymphoma does not get better with treatment. The treatment didn’t work as hoped.
Relapsed: This means the lymphoma came back after being gone for a while after treatment.
2nd line treatment: This is the second treatment you get if the first one didn’t work (refractory) or if the lymphoma comes back (relapse).
3rd line treatment: This is the third treatment you get if the second one didn’t work or the lymphoma comes back again.
Approved: Available in Australia and listed by the Therapeutics Goods Administration (TGA).
Funded: Costs are covered for Australian citizens. This means if you have a Medicare card, you shouldn’t have to pay for the treatment.[WO7]

You need healthy T-cells to make CAR T-cells. For this reason, CAR T-cell therapy cannot be used if you have a T-cell lymphoma – yet.

For more information on CAR T-cells and T-cell lymphoma click here.

Special Note: Although your T-cells are removed from your blood for CAR T-cell therapy, most of our T-cells live outside of our blood – in our lymph nodes, thymus, spleen and other organs.